Factors contributing to peritoneal tissue remodeling in peritoneal dialysis

Peritoneal Dialysis International

Volumn 29, Issue 6, 2009, Pages 605-617

  Schilte, Margot N ^a   Celie, Johanna W A M ^a   Ter Wee, Piet M ^a   Beelen, Robert H J ^a   van den Born, Jacob ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cytokines; Peritoneal cells; Peritoneal rest; Therapeutic interventions; Tissue remodeling

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; AQUAPORIN 1; BASIC FIBROBLAST GROWTH FACTOR; BUFFER; CYCLOOXYGENASE 2; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; LACTIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PERITONEAL DIALYSIS FLUID; PROSTAGLANDIN E2; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CAPILLARY ENDOTHELIUM; CELL ACTIVATION; CELL DIFFERENTIATION; CELL LOSS; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DIALYSIS CATHETER; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROSIS; HUMAN; INFLAMMATION; LYMPHANGIOGENESIS; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MEMBRANE; MESOTHELIUM; MESOTHELIUM CELL; MYOFIBROBLAST; NONHUMAN; OMENTUM; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEAL INFLAMMATION; PERITONEAL MEMBRANE; PERITONEUM; PERITONEUM MACROPHAGE; PERITONEUM MAST CELL; PERITONITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE REMODELING; TISSUE STRUCTURE; ULTRAFILTRATION; UREMIA;

EID: 77951696103     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.1177/089686080902900604     Document Type: Review

References (128)

1. Hekking LH, van den Born J. Feasibility of mesothelial transplantation during experimental peritoneal dialysis and peritonitis. Int J Artif Organs 2007; 30(6):513-19.
2. Schilte MN, Loureiro J, Keuning ED, ter Wee PM, Celie JWAM, Beelen RH, et al. Long-term intervention with heparins in a rat model for peritoneal dialysis. Perit Dial Int 2009; 29(1):26-35.
3. Zareie M, Hekking LH, Welten AG, Driesprong BA, Schadee- Eestermans IL, Faict D, et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18(12):2629-37.
4. Zareie M, De Vriese AS, Hekking LH, ter Wee PM, Schalkwijk CG, Driesprong BA, et al. Immunopathological changes in a uraemic rat model for peritoneal dialysis. Nephrol Dial Transplant 2005; 20(7):1350-61.
5. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells [Published correction appears in N Engl J Med 2005; 353(26):2827]. N Engl J Med 2003; 348(5):403-13.
6. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Greeuw I, et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 2001; 12(12):2775-86.
7. Fusshoeller A. Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis. Pediatr Nephrol 2008; 23(1):19-25.
8. Zareie M, Keuning ED, ter Wee PM, Schalkwijk CG, Beelen RH, van den Born J. Improved biocompatibility of bicarbonate/ lactate-buffered PDF is not related to pH. Nephrol Dial Transplant 2006; 21(1):208-16.
9. Di Paolo N, Sacchi G, Garosi G, Sansoni E, Bargagli L, Ponzo P, et al. Omental milky spots and peritoneal dialysis-review and personal experience. Perit Dial Int 2005; 25(1):48-57.
10. Beelen RHJ, Oosterling SJ, van Egmond M, van den Born J, Zareie M. Omental milky spots in peritoneal pathophysiology (spots before your eyes). Perit Dial Int 2005; 25(1):30-2.
11. Lai KN, Tang SC, Leung JC. Mediators of inflammation and fibrosis. Perit Dial Int 2007; 27(Suppl 2):S65-71.
12. Michels WM, Zweers MM, Smit W, Korevaar J, Struijk DG, van Westrhenen R, et al. Does lymphatic absorption change with the duration of peritoneal dialysis? Perit Dial Int 2004; 24(4):347-52.
13. Chan TM, Yung S. Studying the effects of new peritoneal dialysis solutions on the peritoneum. Perit Dial Int 2007; 27(Suppl 2):S87-93.
14. Jorres A, Bender TO, Finn A, Witowski J, Frohlich S, Gahl GM, et al. Biocompatibility and buffers: effect of bicarbonate- buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998; 54(6):2184-93.
15. Flessner MF, Credit K, Henderson K, Vanpelt HM, Potter R, He Z, et al. Peritoneal changes after exposure to sterile solutions by catheter. J Am Soc Nephrol 2007; 18(8):2294-302.
16. Wieczorowska-Tobis K, Polubinska A, Schaub TP, Schilling H, Wisniewska J, Witowski J, et al. Influence of neutralpH dialysis solutions on the peritoneal membrane: a longterm investigation in rats. Perit Dial Int 2001; 21(Suppl 3): S108-13.
17. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate/ lactate-buffered dialysis solution in a rat model. Kidney Int 2005; 67(4):1559-65.
18. Musi B, Braide M, Carlsson O, Wieslander A, Albrektsson A, Ketteler M, et al. Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats. Perit Dial Int 2004; 24(1):37-47.
19. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14(6):1541-9.
20. Kim CD, Kwon HM, Park SH, Oh EJ, Kim MH, Choi SY, et al. Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascularization in a chronic rat model. Ther Apher Dial 2007; 11(1):56-64.
21. Lee EA, Oh JH, Lee HA, Kim SI, Park EW, Park KB, et al. Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: role of aminoguanidine. Perit Dial Int 2001; 21(3):245-53.
22. Zareie M, Tangelder GJ, ter Wee PM, Hekking LH, van Lambalgen AA, Keuning ED, et al. Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD. Nephrol Dial Transplant 2005; 20(12):2783-92.
23. Mortier S, De Vriese AS, Lameire N. Recent concepts in the molecular biology of the peritoneal membrane-implications for more biocompatible dialysis solutions. Blood Purif 2003; 21(1):14-23.
24. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13(2):470-9.
25. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P, Miyata T, et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001; 12(10):2146-57.
26. Verger C, Luger A, Moore HL, Nolph KD. Acute changes in peritoneal morphology and transport properties with infectious peritonitis and mechanical injury. Kidney Int 1983; 23(6):823-31.
27. Tekstra J, Visser CE, Tuk CW, Brouwer-Steenbergen JJ, Burger CW, Krediet RT, et al. Identification of the major chemokines that regulate cell influxes in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7(11):2379-84.
28. Lewis S, Holmes C. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. 1. Perit Dial Int 1991; 11(1):14-21.
29. Peterson PK, Gaziano E, Suh HJ, Devalon M, Peterson L, Keane WF. Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages. Infect Immun 1985; 49(1):212-18.
30. Bauermeister K, Burger M, Almanasreh N, Knopf HP, Schumann RR, Schollmeyer P, et al. Distinct regulation of IL-8 and MCP-1 by LPS and interferon-gamma-treated human peritoneal macrophages. Nephrol Dial Transplant 1998; 13(6):1412-19.
31. Topley N. The cytokine network controlling peritoneal inflammation. Perit Dial Int 1995; 15(7 Suppl):S35-9.
32. Lee SK, Kim BS, Yang WS, Kim SB, Park SK, Park JS. High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. Kidney Int 2001; 60(1):55-64.
33. Topley N, Mackenzie R, Jorres A, Coles GA, Davies M, Williams JD. Cytokine networks in continuous ambulatory peritoneal dialysis: interactions of resident cells during inflammation in the peritoneal cavity. Perit Dial Int 1993; 13(Suppl 2):S282-5.
34. Dobbie JW, Anderson JD, Hind C. Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 1994; 14(Suppl 3):S16-20.
35. Hekking LH, Zweers MM, Keuning ED, Driesprong BA, de Waart DR, Beelen RH, et al. Apparent successful mesothelial cell transplantation hampered by peritoneal activation. Kidney Int 2005; 68(5):2362-7.
36. Mutsaers SE, Whitaker D, Papadimitriou JM. Mesothelial regeneration is not dependent on subserosal cells. J Pathol 2000; 190(1):86-92.
37. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11(4):729-39.
38. Horiuchi T, Miyamoto K, Miyamoto S, Fujita M, Sano N, Minamiyama K, et al. Image analysis of remesothelialization following chemical wounding of cultured human peritoneal mesothelial cells: the role of hyaluronan synthesis. Kidney Int 2003; 64(6):2280-90.
39. Witkowicz J. Mesothelial cell transplantation. Pol Arch Med Wewn 2008; 118(5):307-13.
40. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, West- Mays JA, et al. Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16(2):425-36.
41. Aroeira LS, Aguilera A, Selgas R, Ramirez-Huesca M, Perez- Lozano ML, Cirugeda A, et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005; 46(5):938-48.
42. Zhang J, Oh KH, Xu H, Margetts PJ. Vascular endothelial growth factor expression in peritoneal mesothelial cells undergoing transdifferentiation. Perit Dial Int 2008; 28(5):497-504.
43. Vargha R, Endemann M, Kratochwill K, Riesenhuber A, Wick N, Krachler AM, et al. Ex vivo reversal of in vivo transdifferentiation in mesothelial cells grown from peritoneal dialysate effluents. Nephrol Dial Transplant 2006; 21(10):2943-7.
44. Aguilera A, Aroeira LS, Ramirez-Huesca M, Perez-Lozano ML, Cirugeda A, Bajo MA, et al. Effects of rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells. Int J Artif Organs 2005; 28(2):164-9.
45. Alscher DM, Braun N, Biegger D, Fritz P. Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am J Kidney Dis 2007; 49(3):452-61.
46. Jimenez-Heffernan JA, Bajo MA, Perna C, Del Peso G, Larrubia JR, Gamallo C, et al. Mast cell quantification in normal peritoneum and during peritoneal dialysis treatment. Arch Pathol Lab Med 2006; 130(8):1188-92.
47. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77(4):1033-79.
48. Katsanos GS, Anogeianaki A, Orso C, Tete S, Salini V, Antinolfi PL, et al. Mast cells and chemokines. J Biol Regul Homeost Agents 2008; 22(3):145-52.
49. Norrby K. Mast cells and angiogenesis. APMIS 2002; 110(5):355-71.
50. Zareie M, Fabbrini P, Hekking LH, Keuning ED, ter Wee PM, Beelen RH, et al. Novel role for mast cells in omental tissue remodeling and cell recruitment in experimental peritoneal dialysis. J Am Soc Nephrol 2006; 17(12):3447-57.
51. Brouty-Boye D, Pottin-Clemenceau C, Doucet C, Jasmin C, Azzarone B. Chemokines and CD40 expression in human fibroblasts. Eur J Immunol 2000; 30(3):914-19.
52. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 2002; 99(20):12877-82.
53. Aroeira LS, Aguilera A, Sanchez-Tomero JA, Bajo MA, Del Peso G, Jimenez-Heffernan JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007; 18(7):2004-13.
54. Jorres A, Ludat K, Lang J, Sander K, Gahl GM, Frei U, et al. Establishment and functional characterization of human peritoneal fibroblasts in culture: regulation of interleukin- 6 production by proinflammatory cytokines. J Am Soc Nephrol 1996; 7(10):2192-201.
55. Nakagawa H, Ikesue A, Hatakeyama S, Kato H, Gotoda T, Komorita N, et al. Production of an interleukin-8-like chemokine by cytokine-stimulated rat NRK-49F fibroblasts and its suppression by anti-inflammatory steroids. Biochem Pharmacol 1993; 45(7):1425-30.
56. Larsen CG, Anderson AO, Oppenheim JJ, Matsushima K. Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor. Immunology 1989; 68(1):31-6.
57. Flessner MF. Sterile solutions and peritoneal inflammation. Contrib Nephrol 2006; 150:156-65.
58. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23(3):144-50.
59. Okada H, Inoue T, Kanno Y, Kobayashi T, Watanabe Y, Ban S, et al. Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney Int 2003; 64(5):1722-32.
60. Dragomir E, Manduteanu I, Voinea M, Costache G, Manea A, Simionescu M. Aspirin rectifies calcium homeostasis, decreases reactive oxygen species, and increases NO production in high glucose-exposed human endothelial cells. J Diabet Complications 2004; 18(5):289-99.
61. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6(8):2591-9.
62. Zareie M, van Lambalgen AA, De Vriese AS, Van Gelderop E, Lameire N, ter Wee PM, et al. Increased leukocyte rolling in newly formed mesenteric vessels in the rat during peritoneal dialysis. Perit Dial Int 2002; 22(6):655-62.
63. Mortier S, Faict D, Gericke M, Lameire N, De Vriese A. Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane. Nephron Exp Nephrol 2005; 101(4):e139-45.
64. Devuyst O, Nielsen S, Cosyns JP, Smith BL, Agre P, Squifflet JP, et al. Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum. Am J Physiol 1998; 275(1 pt 2):H234-H242.
65. Gesualdo L, Pertosa G, Grandaliano G, Schena FP. Cytokines and bioincompatibility. Nephrol Dial Transplant 1998; 13(7):1622-6.
66. Margetts PJ, Kolb M, Yu L, Hoff CM, Holmes CJ, Anthony DC, et al. Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 2002; 160(6):2285-94.
67. Haslinger B, Mandl-Weber S, Sellmayer A, Sitter T. Hyaluronan fragments induce the synthesis of MCP-1 and IL-8 in cultured human peritoneal mesothelial cells. Cell Tissue Res 2001; 305(1):79-86.
68. Breborowicz A, Korybalska K, Grzybowski A, Wieczorowska-Tobis K, Martis L, Oreopoulos DG. Synthesis of hyaluronic acid by human peritoneal mesothelial cells: effect of cytokines and dialysate. Perit Dial Int 1996; 16(4):374-8.
69. Ha H, Yu MR, Choi HN, Cha MK, Kang HS, Kim MH, et al. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int 2000; 20(Suppl 5):S10-18.
70. De Vriese AS, Stoenoiu MS, Elger M, Devuyst O, Vanholder R, Kriz W, et al. Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int 2001; 60(1):202-10.
71. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12(10):2029-39.
72. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002; 13(3):721-8.
73. Beavis MJ, Williams JD, Hoppe J, Topley N. Human peritoneal fibroblast proliferation in 3-dimensional culture: modulation by cytokines, growth factors and peritoneal dialysis effluent. Kidney Int 1997; 51(1):205-15.
74. Cina D, Patel P, Bethune JC, Thoma J, Rodriguez-Lecompte JC, Hoff CM, et al. Peritoneal morphological and functional changes associated with platelet-derived growth factor B. Nephrol Dial Transplant 2009; 24(2):448-57.
75. Ogata S, Yorioka N, Kiribayashi K, Naito T, Kuratsune M, Nishida Y. Viability of, and basic fibroblast growth factor secretion by, human peritoneal mesothelial cells cultured with various components of peritoneal dialysis fluid. Adv Perit Dial 2003; 19:2-5.
76. Ogata S, Naito T, Yorioka N, Kiribayashi K, Kuratsune M, Kohno N. Effect of lactate and bicarbonate on human peritoneal mesothelial cells, fibroblasts and vascular endothelial cells, and the role of basic fibroblast growth factor. Nephrol Dial Transplant 2004; 19(11):2831-7.
77. Roubin R, Benveniste J. Formation of prostaglandins, leukotrienes and PAF-acether by macrophages. Comp Immunol Microbiol Infect Dis 1985; 8(2):109-18.
78. Topley N, Petersen MM, Mackenzie R, Neubauer A, Stylianou E, Kaever V, et al. Human peritoneal mesothelial cell prostaglandin synthesis: induction of cyclooxygenase mRNA by peritoneal macrophage-derived cytokines. Kidney Int 1994; 46(3):900-9.
79. Douma CE, de Waart DR, Zemel D, Struijk DG, Krediet RT. Prostaglandin inhibition by intraperitoneal indomethacin has no effect on peritoneal permeability during stable CAPD. Nephrol Dial Transplant 2001; 16(4):803-8.
80. Pool JL. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 2007; 13(8 Suppl B):21-33.
81. Duman S. The renin-angiotensin system and peritoneal dialysis. Perit Dial Int 2004; 24(1):5-9.
82. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002; 82:S12-22.
83. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, et al. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001; 88(1):22-9.
84. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007; 13(8 Suppl B):9-20.
85. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 269(39):24316-20.
86. Juknevicius I, Segal Y, Kren S, Lee R, Hostetter TH. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 2004; 286(6):F1059-F1062.
87. Nakamoto H, Imai H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int 2008; 28(Suppl 3):S83-7.
88. Ersoy R, Celik A, Yilmaz O, Sarioglu S, Sis B, Akan P, et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int 2007; 27(4):424-31.
89. Ha H, Lee HB. Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int 2000; 20(Suppl 2): S15-18.
90. Ha H, Lee HB. Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 2003; 14(8 Suppl 3):S246-9.
91. Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, Uh ST, et al. Role of reactive oxygen species in TGF-beta1-induced mitogenactivated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 2005; 16(3):667-75.
92. Xia L, Wang H, Munk S, Kwan J, Goldberg HJ, Fantus IG, et al. High glucose activates PKC-{zeta} and NADPH oxidase through autocrine TGF-{beta}1 signaling in mesangial cells. Am J Physiol Renal Physiol 2008; 295(6): F1705-F1714.
93. Noh H, Kim JS, Han KH, Lee GT, Song JS, Chung SH, et al. Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane. Kidney Int 2006; 69(11):2022-8.
94. Williams CS, Mann M, Du Bois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18(55):7908-16.
95. Hilario MO, Terreri MT, Len CA. Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors. J Pediatr (Rio J) 2006; 82(5 Suppl):S206-12.
96. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31(2 Suppl 7):2-11.
97. Shanmugam N, Gaw Gonzalo IT, Natarajan R. Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. Diabetes 2004; 53(3):795-802.
98. Saed GM, Munkarah AR, Diamond MP. Cyclooxygenase-2 is expressed in human fibroblasts isolated from intraperitoneal adhesions but not from normal peritoneal tissues. Fertil Steril 2003; 79(6):1404-8.
99. Fabbrini P, Schilte MN, Zareie M, ter Wee PM, Keuning ED, Beelen RH, et al. Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis. Nephrol Dial Transplant 2009; [in press].
100. Xu ZG, Kim KS, Park HC, Choi KH, Lee HY, Han DS, et al. High glucose activates the p38 MAPK pathway in cultured human peritoneal mesothelial cells. Kidney Int 2003; 63(3):958-68.
101. Mittelstadt PR, Salvador JM, Fornace AJ Jr, Ashwell JD. Activating p38 MAPK: new tricks for an old kinase. Cell Cycle 2005; 4(9):1189-92.
102. Ambrosino C, Nebreda AR. Cell cycle regulation by p38 MAP kinases. Biol Cell 2001; 93(1-2):47-51.
103. Ryan S, McNicholas WT, Taylor CT. A critical role for p38 MAP kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 2007; 355(3):728-33.
104. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005; 1754(1-2):253-62.
105. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/ p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279(3):1453-61.
106. Carter CA, Kane CJ. Therapeutic potential of natural compounds that regulate the activity of protein kinase C. Curr Med Chem 2004; 11(21):2883-902.
107. Ha H, Lee HB. Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int Suppl 2000; 77:S19-25.
108. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006; 25(4):695-705.
109. Lee HB, Yu MR, Song JS, Ha H. Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int 2004; 65(4):1170-9.
110. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 2002; 13(4):894-902.
111. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315(3):971-9.
112. Cabebe E, Wakelee H. Sunitinib: a newly approved smallmolecule inhibitor of angiogenesis. Drugs Today (Barc) 2006; 42(6):387-98.
113. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7(3):225-33.
114. Neef M, Ledermann M, Saegesser H, Schneider V, Widmer N, Decosterd LA, et al. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol 2006; 44(1):167-75.
115. Welten AG, Schalkwijk CG, ter Wee PM, Meijer S, van den Born J, Beelen RJ. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 2003; 23(3):213-21.
116. Boulanger E, Grossin N, Wautier MP, Taamma R, Wautier JL. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 2007; 71(2):126-33.
117. Schwenger V. GDP and AGE receptors: mechanisms of peritoneal damage. Contrib Nephrol 2006; 150:77-83.
118. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17(1):199-207.
119. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal mem- brane. J Am Soc Nephrol 2003; 14(8):2109-18.
120. Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB. Inhibition of the JAK/STAT signaling pathway prevents the high glucose-induced increase in TGF-beta and fibronectin synthesis in mesangial cells. Diabetes 2002; 51(12):3505-9.
121. Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect 2005; 18(4):243-9.
122. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290(4):F762-F768.
123. Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 2002; 61(5):1605-16.
124. Rodrigues A, Cabrita A, Maia P, Guimaraes S. Peritoneal rest may successfully recover ultrafiltration in patients who develop peritoneal hyperpermeability with time on continuous ambulatory peritoneal dialysis. Adv Perit Dial 2002; 18:78-80.
125. de Alvaro F, Castro MJ, Dapena F, Bajo MA, Fernandez- Reyes MJ, Romero JR, et al. Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 1993; 9:56-61.
126. Zhe XW, Tian XK, Cheng L, Wang T. Effects of peritoneal resting on peritoneal fluid transport kinetics. Perit Dial Int 2007; 27(5):575-9.
127. Kim YL, Kim SH, Kim JH, Kim SJ, Kim CD, Cho DK, et al. Effects of peritoneal rest on peritoneal transport and peritoneal membrane thickening in continuous ambulatory peritoneal dialysis rats. Perit Dial Int 1999; 19(Suppl 2): S384-7.
128. Zareie M, Keuning ED, ter Wee PM, Beelen RH, van den Born J. Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats. Nephrol Dial Transplant 2005; 20(1):189-93.